These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
398 related articles for article (PubMed ID: 28290186)
1. Phosphorus and other aspects of CKD-MBD in the conservative management of chronic kidney disease. Shah A Panminerva Med; 2017 Jun; 59(2):124-132. PubMed ID: 28290186 [TBL] [Abstract][Full Text] [Related]
2. Survey of attitudes of physicians toward the current evaluation and treatment of chronic kidney disease-mineral and bone disorder (CKD-MBD). Souqiyyeh MZ; Shaheen FA Saudi J Kidney Dis Transpl; 2010 Jan; 21(1):93-101. PubMed ID: 20061700 [TBL] [Abstract][Full Text] [Related]
3. Association of Vitamin D Metabolites with Parathyroid Hormone, Fibroblast Growth Factor-23, Calcium, and Phosphorus in Dogs with Various Stages of Chronic Kidney Disease. Parker VJ; Harjes LM; Dembek K; Young GS; Chew DJ; Toribio RE J Vet Intern Med; 2017 May; 31(3):791-798. PubMed ID: 28186657 [TBL] [Abstract][Full Text] [Related]
4. [Management of bone and mineral metabolism disorders before the dialysis stage remains still perfectible. Data from the French Phosphorus and Calcium Survey Photo-Graphe]. Jean G; Daugas É; Roth H; Drueke T; Bouchet JL; Hannedouche T; London G; Fouque D Nephrol Ther; 2017 Nov; 13(6):470-478. PubMed ID: 28843391 [TBL] [Abstract][Full Text] [Related]
5. Management of CKD-MBD in non-dialysis patients under regular nephrology care: a prospective multicenter study. Gallieni M; De Luca N; Santoro D; Meneghel G; Formica M; Grandaliano G; Pizzarelli F; Cossu M; Segoloni G; Quintaliani G; Di Giulio S; Pisani A; Malaguti M; Marseglia C; Oldrizzi L; Pacilio M; Conte G; Dal Canton A; Minutolo R J Nephrol; 2016 Feb; 29(1):71-8. PubMed ID: 25986389 [TBL] [Abstract][Full Text] [Related]
6. CKD, arterial calcification, atherosclerosis and bone health: Inter-relationships and controversies. Reiss AB; Miyawaki N; Moon J; Kasselman LJ; Voloshyna I; D'Avino R; De Leon J Atherosclerosis; 2018 Nov; 278():49-59. PubMed ID: 30253289 [TBL] [Abstract][Full Text] [Related]
7. Trends of elevated parathormone serum titers in hemodialysis patients on intensive therapy for bone disease: a multicenter study. Karkar A; Sinha AK; Abdelrahman M; Mushtaque F; Awn NM; Qadi Y; Nassar M; Algareeb A; Taha MI; Abdulkader M; Sabry A; Souqiyyeh MZ; Shaheen FA Saudi J Kidney Dis Transpl; 2014 Nov; 25(6):1166-77. PubMed ID: 25394432 [TBL] [Abstract][Full Text] [Related]
8. Integral pharmacological management of bone mineral disorders in chronic kidney disease (part I): from treatment of phosphate imbalance to control of PTH and prevention of progression of cardiovascular calcification. Bover J; Ureña-Torres P; Lloret MJ; Ruiz-García C; DaSilva I; Diaz-Encarnacion MM; Mercado C; Mateu S; Fernández E; Ballarin J Expert Opin Pharmacother; 2016 Jun; 17(9):1247-58. PubMed ID: 27156993 [TBL] [Abstract][Full Text] [Related]
9. Prevention and control of phosphate retention/hyperphosphatemia in CKD-MBD: what is normal, when to start, and how to treat? Martin KJ; González EA Clin J Am Soc Nephrol; 2011 Feb; 6(2):440-6. PubMed ID: 21292848 [TBL] [Abstract][Full Text] [Related]
10. Chronic kidney disease patients who smoke have higher serum phosphorus. Santos GDD; Elias RM; Dalboni MA; Silva GVD; Moysés RMA J Bras Nefrol; 2019; 41(2):288-292. PubMed ID: 30534856 [TBL] [Abstract][Full Text] [Related]
11. [Changes in mineral metabolism in stage 3, 4, and 5 chronic kidney disease (not on dialysis)]. Lorenzo Sellares V; Torregrosa V Nefrologia; 2008; 28 Suppl 3():67-78. PubMed ID: 19018742 [TBL] [Abstract][Full Text] [Related]
13. [New Developments in CKD-MBD. Strategies for the management of predilalysis CKD-MBD]. Ando R Clin Calcium; 2014 Dec; 24(12):1845-51. PubMed ID: 25423931 [TBL] [Abstract][Full Text] [Related]
14. Crosstalk between kidney and bone: insights from CKD-MBD. Suzuki K; Soeda K; Komaba H J Bone Miner Metab; 2024 Jul; 42(4):463-469. PubMed ID: 39060498 [TBL] [Abstract][Full Text] [Related]
15. Phosphate binders, vitamin D and calcimimetics in the management of chronic kidney disease-mineral bone disorders (CKD-MBD) in children. Wesseling-Perry K; Salusky IB Pediatr Nephrol; 2013 Apr; 28(4):617-25. PubMed ID: 23381010 [TBL] [Abstract][Full Text] [Related]
16. Osteoporosis in Patients with Chronic Kidney Diseases: A Systemic Review. Hsu CY; Chen LR; Chen KH Int J Mol Sci; 2020 Sep; 21(18):. PubMed ID: 32961953 [TBL] [Abstract][Full Text] [Related]
17. [Bone mineral metabolism in patients with chronic kidney disease: review of its pathophysiology and morbimortality]. Bernuy J; Gonzales GF Rev Peru Med Exp Salud Publica; 2015; 32(2):326-34. PubMed ID: 26338395 [TBL] [Abstract][Full Text] [Related]
18. Mechanistic insights into CKD-MBD-related vascular calcification and its clinical implications. Kaur R; Singh R Life Sci; 2022 Dec; 311(Pt B):121148. PubMed ID: 36336124 [TBL] [Abstract][Full Text] [Related]
19. Effects of unfractionated heparin on renal osteodystrophy and vascular calcification in chronic kidney disease rats. Meng Y; Zhang H; Li Y; Li Q; Zuo L Bone; 2014 Jan; 58():168-76. PubMed ID: 24145307 [TBL] [Abstract][Full Text] [Related]
20. Utilization and costs of medications associated with CKD mineral and bone disorder in dialysis patients enrolled in Medicare Part D. Yusuf AA; Howell BL; Powers CA; St Peter WL Am J Kidney Dis; 2014 Nov; 64(5):770-80. PubMed ID: 24833203 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]